Special Issue "Diagnosis and Treatment of IgA Nephropathy and IgA Vasculitis Nephritis in Children"
Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 6168
Interests: pediatric nephrology; children immune-mediated kidney disorders; IgA nephropathy and IgA vasculitis; pediatric kidney transplantation; congenital genetic based kidney diseases
IgA nephropathy (IgAN) is the most common glomerulonephritis at any age, starting from childhood. Pediatricians often deal with a mild disease, with recurrent macroscopic hematuria or persistent microscopic hematuria, rarely progressing to chronic kidney disease (CKD) stage 5 within their observation period.
IgA vasculitis is quite common in children, and the renal involvement—when present—is mostly self-limiting and benign, but in some cases is hampered by an explosive and aggressive onset or an even more dangerous smoldering progression.
After transition to adulthood the oft-neglected occurrence of proteinuria and hypertension may lead to the relentless loss of 50% of renal function in up to 40% of patients after 20 years in both diseases.
There is therefore a need to widen the perspective of pediatricians and pediatric nephrologists beyond the pediatric age to evaluate the risk of progression and adopt the best treatment to ensure the interruption of the progression of both diseases before the point of no return is reached.
The management of children requires the consideration of all the forecasted risk factors to choose the most appropriate treatment scheme and tailor the follow up.
In this Special Issue, an update on the available tools to estimate the risk factors for progression with the help of new biomarkers and a new look to old and well-known clinical and pathological risk factors will be provided to widen the point of view of pediatricians faced with the high responsibility of choosing the right treatment to provide a long and high-quality life expectancy.
We are soliciting new research papers on IgAN and IgAVN, including clinical, pathology, genetic biomarkers.
We also welcome the submission of brief state-of-the-art papers on therapy, genetics, biomarkers, and risk factor estimation tools.
Dr. Licia Peruzzi
Prof. Dr. Rosannna Coppo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- IgA nephropathy
- IgA vasculitis nephritis
- immunoglobulin A
- risk factors